The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Abstract
CONTEXT: Short-term data on the immunogenicity of monoclonal antibodies showed associations between the development of antidrug antibodies and diminished serum drug levels, and a diminished treatment response. Little is known about the clinical relevance of antidrug antibodies against these drugs during long-term follow-up. OBJECTIVE: To examine the course of antidrug antibody formation against fully human monoclonal antibody adalimumab and its clinical relevance during long-term (3-year) follow-up of patients with rheumatoid arthritis (RA). DESIGN, SETTING, AND PATIENTS: Prospective cohort study February 2004-September 2008; end of follow-up was September 2010. All 272 patients were diagnosed with RA and started treatment with adalimumab in an outpatient clinic. MAIN OUTCOME MEASURES: Disease activity was monitored and trough serum samples were obtained at baseline and 8 time points to 156 weeks. Serum adalimumab concentrations and antiadalimumab antibody titers were determined after follow-up. Treatment discontinuation, minimal disease activity, and clinical remission were compared for patients with and without antiadalimumab antibodies. RESULTS: After 3 years, 76 of 272 patients (28%) developed antiadalimumab antibodies--51 of these (67%) during the first 28 weeks of treatment. Patients without antiadalimumab antibodies had much higher adalimumab concentrations (median, 12 mg/L; IQR, 9-16 mg/L) compared with patients with antibody titers from 13 to 100 AU/mL (median, 5 mg/L; IQR, 3-9 mg/L; regression coefficient, -4.5; 95% CI, -6.0 to -2.9; P < .001) and also those greater than 100 AU/mL (median, 0 mg/L; IQR, 0-3 mg/L; regression coefficient, -7.1; 95% CI, -8.4 to -5.8; P < .001). Patients with antiadalimumab antibodies more often discontinued participation due to treatment failure (n = 29 [38%]; hazard ratio [HR], 3.0; 95% CI, 1.6-5.5; P < .001) compared with antiadalimumab antibody-negative ones (n = 28 [14%]). Ninety-five of 196 patients (48%) without antiadalimumab antibodies had minimal disease activity vs 10 of 76 patients (13%) with antiadalimumab antibodies; patients with antiadalimumab antibodies less often had sustained minimal disease activity score in 28 joints (DAS28) (< 3.2; HR, 3.6; 95% CI, 1.8-7.2; P < .001) compared with antiadalimumab antibody-negative ones. Three of 76 patients (4%) with antiadalimumab antibodies achieved sustained remission compared with 67 of 196 (34%) antiadalimumab antibody-negative ones; patients with antiadalimumab antibodies less often achieved remission (DAS28 < 2.6; HR, 7.1; 95% CI, 2.1-23.4; P < .001) compared with antiadalimumab antibody-negative ones. CONCLUSION: Among outpatients with RA in whom adalimumab was started over 3 years, the development of antidrug antibodies was associated with lower adalimumab concentration and lower likelihood of minimal disease activity or clinical remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Vermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., Dijkmans, B. A. C., Tak, P. P., & Wolbink, G. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065615 · Cited by 562
Self-citationKarmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 384
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277457.17420.b5 · Cited by 339
Cited by
Methotrexate mechanism in treatment of rheumatoid arthritis
Friedman, B., & Cronstein, B. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.07.004 · Cited by 439
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
Jantan, I., Ahmad, W., & Bukhari, S. N. A. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00655 · Cited by 409
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Shankar, G., Arkin, S., Cocea, L., Devanarayan, V., Kirshner, S., Kromminga, A., Quarmby, V., Richards, S., Schneider, C. K., Subramanyam, M., et al. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9599-2 · Cited by 353
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Strand, V., Balsa, A., Al-Saleh, J., Barile-Fabris, L., Horiuchi, T., Takeuchi, T., Lula, S., Hawes, C., Kola, B., & Marshall, L. (2017) · BioDrugs · doi:10.1007/s40259-017-0231-8 · Cited by 353
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.12 · Cited by 346
Biologic agents for IBD: practical insights
Danese, S., Vuitton, L., & Peyrin-Biroulet, L. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.135 · Cited by 342
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 292
Roblin, X., Marotte, H., Rinaudo, M., Del Tedesco, E., Moreau, A., Phelip, J. M., Genin, C., Peyrin–Biroulet, L., & Paul, S. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.010 · Cited by 279
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
Immunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131
Evaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
Bendtzen, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00109 · Cited by 73
Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events
Prado, M. S., Bendtzen, K., & Andrade, L. E. C. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1360280 · Cited by 58
Uchino, T., Miyazaki, Y., Yamazaki, T., & Kagawa, Y. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12765 · Cited by 49
Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies
Bitoun, S., Hässler, S., Ternant, D., Szely, N., Gleizes, A., Richez, C., Soubrier, M., Avouac, J., Brocq, O., Sellam, J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23098 · Cited by 43
Taylor, P. C., Schiff, M. H., Wang, Q., Jiang, Y., Zhuang, Y., Kurrasch, R., Daga, S., Rao, R., Tak, P. P., & Hsu, B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212496 · Cited by 28
Proactively Reducing Anti‐Drug Antibodies via Immunomodulatory Bioconjugation
Zhang, P., Jain, P., Tsao, C., Wu, K., & Jiang, S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201814275 · Cited by 18
Proactively reducing anti-drug antibodies via immunomodulatory bioconjugation
Zhang, P., Jain, P., Tsao, C., Wu, K., & Jiang, S. (2019) · Angewandte Chemie · doi:10.1002/ange.201814275 · Cited by 4
Metadata
- Authors
- Bartelds, G. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-04-13
- Volume
- 305
- Issue
- 14
- Pages
- 1460
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2149065814
- Cited by
- 782
- References
- 22
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.